AMGEN and Repatha at ACC

COUNT ON US

because your patients
are counting on you

JOIN US for live virtual product theater

Repatha®

Saturday, May 15

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

10:15 AM–11:15 AM ET

Learn more

Repatha®

Sunday, May 16

Richard F. Wright, MD, FACC

3:45 PM–4:45 PM ET

Learn more

Repatha® added to a statin can dramatically lower LDL-C and reduce the risk of another MI1

JOIN US for live
virtual product theater

Repatha®

Saturday, May 15

Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC

10:15 AM–11:15 AM ET

Learn more

Repatha®

Sunday, May 16

Richard F. Wright, MD, FACC

3:45 PM–4:45 PM ET
 

Learn more

Robust experience with Repatha®:

Data from clinical trials
and the real world

In addition to clinical trials, an estimated

>1,000,000

patients have received Repatha® in the
5 years since launch2,*

50
evolocumab clinical trials3

>47,000
patients were studied3,†

Includes patients randomized to Repatha® or placebo.1

*Cumulative post-market exposure estimates from July 2015 through March 31, 2021, on patients that have received at least one dose administration of the product. The number of patients receiving at least one administration is estimated using worldwide unit sales data, prescription claims data, and applying utilization assumptions to calculate the unique number of patients. Sources include Amgen Finance Electronic Data Warehouse, IQVIA prescription claims, and Marketscan claims data. The estimates assume patient self-administration based on filled prescriptions.3

FEATURED CONTENT

Explore Repatha® clinical evidence in the FOURIER, EVACS, and EVOPACS trials

Learn more

Find out about the access and affordability of Repatha® for your patients

Learn more

References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Data on file, Amgen; [1]; 2021. 3. Data on file, Amgen; [2]; 2021.

IMPORTANT SAFETY INFORMATION
  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please click red ^ to view additional Important Safety Information.

Please see full Prescribing Information.